ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Galecto raises $64 million to boost fibrosis, cancer pipelines

by Megha Satyanarayana
October 2, 2020 | APPEARED IN VOLUME 98, ISSUE 38

 

Galecto, a biotech company developing treatments for diseases like nonalcoholic steatohepatitis and pulmonary fibrosis, has raised $64 million from Soleus Capital and Eir Ventures, among others. The company has several candidates in clinical trials, including GB0139, for use in idiopathic pulmonary fibrosis, and GB1211, a treatment for liver fibrosis. The company’s treatments focus on modulating galectin-3, involved in inflammation, and LOXL2, which is dysregulated in cancers.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment